Recent Updates — SEER
The Special Committee of Seer’s Board of Directors has unanimously rejected recent unsolicited, non-binding acquisition proposals for the company. The board determined that offers including a $2.55 per share cash price plus contingent value rights from the Radoff-JEC Group and a $2.45 per share offer from CEO Omid Farokhzad fail to reflect Seer’s intrinsic value. Consequently, Seer will remain an independent public company rather than pursuing a sale at this time. The company operates in the biotechnology sector, providing deep proteomic insights through its proprietary Proteograph product suite.
On September 14, 2026, David Horn resigned as President, CFO, and Treasurer of Seer, Inc., effective October 1, 2026, to pursue other interests. The resignation was not due to disagreements with the company regarding operations. In connection with this departure, the Board appointed Omid Farokhzad, M.D., currently CEO and Chair, as President on an additional basis, effective October 1, 2026. Charles Endweiss, Vice President of Financial Planning & Analysis since January 2021, was appointed Treasurer, Principal Financial Officer, and Principal Accounting Officer, also effective October 1, 2026. Mr. Endweiss previously served as Head of Business Operations at Carbon. The company extended the post-termination exercise period for Mr. Horn's vested options to one year following his last day of service, contingent upon executing a separation agreement. Seer, Inc. operates in the genomics and precision medicine industry, providing comprehensive genomic profiling services.
Seer, Inc. reported second quarter 2026 financial results with revenue of $3.1 million, a 23% decrease from the prior year period, driven by macroeconomic headwinds and elongated sales cycles. The company posted a net loss of $16.9 million compared to $19.4 million in the previous year, while maintaining full-year 2026 revenue guidance between $16 million and $18 million. Seer ended the quarter with approximately $209.5 million in cash, cash equivalents, and investments, and repurchased roughly 200,000 Class A common shares under its existing buyback program. Additionally, the company initiated an International Trade Commission investigation against Nanomics Biotechnology for alleged patent infringement and secured a favorable European Patent Office ruling regarding its licensed technology. Seer operates in the biotechnology industry, providing deep proteomic insights through its proprietary Proteograph product suite.
Seer, Inc. confirmed receipt of two revised, non-binding acquisition proposals to acquire all outstanding Class A common shares. On July 28, 2026, the Radoff-JEC Group offered $2.55 per share in cash plus a contingent value right (CVR). On July 29, 2026, CEO Omid Farokhzad submitted a revised proposal offering $2.45 per share in cash plus two CVRs, potentially delivering up to $7.69 per share if revenue and sale milestones are met. The Special Committee will review these offers alongside other alternatives. Seer, Inc. operates in the biotechnology industry, providing deep proteomic insights through its Proteograph product suite.
On July 20, 2026, Seer, Inc. announced that a Special Committee of its Board of Directors unanimously rejected an unsolicited, non-binding proposal from Chair and CEO Omid Farokhzad, M.D., received on July 1, 2026. The proposal sought to acquire all outstanding Class A common stock for $2.45 per share in cash plus two contingent value rights. The Special Committee determined the offer undervalued the company and its long-term growth prospects. Seer operates in the biotechnology industry, providing a proteomic product suite for deep, unbiased proteomics research.